INTRODUCTION
Activins are proteins of gonadal origin which stimulate FSH release in vitro (1 -3) . Two forms of activin have been isolated from porcine follicular fluid and shown to be either a disulfide-linked homodimer of the inhibin /3 Asubunit (activin-A) or a heterodimer composed of a /3 Aand a /8 B -subunit protein (activin AB) (1) (2) (3) . Activin A has also been shown to promote differentiation of a variety of erythroleukemic cells in vitro and synergize with erythropoietin in stimulating erythroid colony formation in primary bone marrow cultures (4) (5) (6) . It has been reported previously that inhibin A («j8 A ) and inhibin B (a/?p) exist in porcine follicular fluid. Inhibin A and inhibin B have similar biological potencies in the rat primary pituitary assay (7) , and inhibin A has been shown to antagonize the actions of activin A on K562 cells and bone marrow cultures (5, 6) . Activin B (/3 B ifyj) has never been isolated from follicular fluid, suggesting 0888-8809/89/1352-1358$02.00/0 Molecular Endocrinology Copyright © 1989 by The Endocrine Society that it is either not synthesized or is present at much lower levels than activin A and activin AB. In the present study we sought to synthesize activin B firstly to ascertain whether such a molecule could be formed and secondly to determine if it possesses similar biological activities and potencies as those of the two previously described activins.
RESULTS

Complete Sequence of £ B Precursor
In our earlier work (8) we reported a partial cDNA sequence of the human inhibin /Vsubunit. Subsequent attempts at obtaining full-length cDNA clones from specifically primed cDNA libraries were frustrated by the presence of a GC-rich sequence at the 5' end of the /3 B mRNA. Translation of the longer /3 B cDNA clones started with an unusual proline-rich sequence. To confirm this sequence information, a Charon 4A human genomic library was screened with an oligonucleotide whose sequence was derived from the 5' end of a /3 B cDNA clone. One X clone was obtained and restriction enzyme mapping revealed a 12-kilobase (kb) EcoRI fragment which hybridized to both 5' and 3' end /3 B DNA probes. The 12-kb EcoRI fragment was subcloned into pBR322, and a detailed restriction map was deduced as shown in Fig. 1A . A 600-basepair (bp) Pst\ fragment and an 800-bp SamHI fragment which hybridized to the 5'-oligonucleotide were subcloned into M13 vectors and completely sequenced. The complete sequence of the 5' end of the 0 B gene, commencing at a SamHI site, is shown in Fig. 1B . Translation of the DNA sequence revealed an open reading frame colinear with the previously deduced protein sequence. An initiator methionine was followed by a characteristically hydrophobic signal sequence and the proline-rich sequence previously observed in j8 B cDNA clones. This sequence predicts a prepro inhibin j8 B -subunit of 407 amino acids. The proline-rich region, which contains 12 proline residues in the space of 16 residues, is located between the signal sequence and the first two cysteine residues 
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7 0 8 0 The p B coding sequences are contained within two exons, with a 2.5-kb intron splitting the sequence at amino acid position 169 (Fig. 1B) . No TATAAA-like sequence is present in the 5' flanking region of the /3 B gene, which is extremely GC rich. The 5' flanking sequence contains a total of eight potential Sp1 -binding sites, with the first one located 85 bp 5' of the initiator ATG (9,10). Mammalian and viral promoters which use Sp1 generally have the cap site located 40-70 bp 3' of the first Sp1-binding sites (10) . Although the 5' end of the /3 B mRNA has not been mapped, it is tempting to postulate that the cap site or sites are located within the 85 bp 3' of the first Sp1-binding site. The sequence 5' of the Sp1-rich sequence contains three potential cAMP regulatory sequences (11). This is not unexpected, since Sertoli cell production of inhibin has been shown to be up-regulated by cAMP via the actions of FSH (12) . This is likely to involve the /3 B gene, since it is the major /3-chain expressed in adult male rats (13) . We cannot discount that further 5' exons may exist within the 5' untranslated sequence of the /3 B gene.
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Expression of Activin B
To construct a full-length coding sequence for the p Bsubunit, a 5' end genomic fragment of the /3 B gene was linked in frame to a partial /? B cDNA clone, as outlined in Fig. 2 . This DNA fragment containing the complete coding region was inserted into a cytomegalovirus promoter expression vector, creating the plasmid pRK/3 B (14, 15) . A mammalian kidney cell line transfected with pRKj8 B was shown by metabolic labeling to secrete a band of about 22K mol wt (Fig. 3, lane 5) . The 22K protein was reduced with /S-mercaptoethanol to a band of approximately 14K, suggesting that it represents a /? B dimer (data not shown). Supernatants from cells transfected with pRK/3 B stimulated FSH release in a primary rat pituitary cell assay (data not shown). These data suggest that a j8 B homodimer can be formed and that it displays an activin-like activity on cultured pituitary cells.
Mammalian cells cotransfected with equimolar amounts of an activin A and activin B expression vectors secrete a mixture of three bands in the 24-22K range (Fig. 3A, lane 4) . The 24K and 22K bands are activin A and activin B as seen by comparison with cell lines secreting either activin A or activin B (Fig. 3A, lane   3 and 5) . The 23K band represents a heterodimer of a /8 A -and /? B -chain, as confirmed by immune precipitations with antibodies specific for the j8 A chain (Fig. 3B, lane  5) . The amounts of both homodimers formed are significantly greater than that of the heterodimer, suggesting that each chain preferentially forms homodimers. As previously shown for activin A biosynthesis, the pro region of ft» precursor is secreted as an approximately 40K band with the activin dimer. Unpublished observations suggest that the pro region of the activins may function as a binding protein for the activin dimer, and that the mature and pro regions are secreted as a noncovalently linked complex.
To construct a stable cell line secreting activin B, a mammalian kidney cell line was cotransfected with pRK/? B and a plasmid containing a neomycin resistance gene. A total of 24 G418 resistant clones were screened for activin B secretion by metabolic labeling. Supernatants from each of the clones that secreted the 22K /3 B dimer were shown to contain biologically competent activin B, as judged by the rat pituitary bioassay (data not shown). Using purified recombinant activin A as a standard, clone 1106 was found to secrete between 1 -2 Mg/ml activin-like biological activity. Forty liters of clone 1106 were grown up in roller bottles, and the supernatants were used as starting material to purify activin B. Standard protein chemistry methods were used to purify activin B to homogeneity (Schmelzer, C , in preparation).
Biological Activities of Activin B
Purified activin B stimulated FSH secretion by cultured pituitary cells. A representative dose-response curve is shown in Fig. 4A . The ED 50 was 2.1 ± 0.6 ng/ml (mean ± SEM; n = 5), which is comparable to that for activin A [2.1 ± 1 . 1 ng/ml (mean ± SD); n = 2]. Purified activin B also stimulated hemoglobin accumulation in the K562 human erythroleukemia cell line (Fig. 4B) . The ED 50 in this assay was 2.2 ± 0.4 ng/ml (mean ± SE; n = 5), which again agrees well with that obtained for activin A (14) .
DISCUSSION
In this study we have determined the complete amino acid sequence of the prepro form of human inhibin fi Bsubunit. The human /5 B gene was shown to consist of two exons which contain all of the coding sequences; this is analogous to the genes for the human a and /? A inhibin subunits (Mason, A., and L. Berkemeier, in preparation). The conservation of genomic structure suggests a common origin for these three related proteins. Interestingly, the genomic structure of the related transforming growth factor-0 and Mullerian inhibiting substance genes has diverged considerably since these members of the transforming growth factor-/? superfamily are encoded on seven and five exons, respectively (16, 17) presence of consensus cAMP-responsive elements in the flanking region of the p B gene is not unexpected, since it is known that inhibin expression is stimulated by FSH (12) . The functional significance of these sequences is currently being determined by the use of promoter-reporter gene constructs. Interestingly, the a and j8 A inhibin gene flanking sequences do not contain classic TATAAA boxes either (Mason, A., and L. Berkemeir).
Comparison of the j8 A and p B prepro amino acid sequences revealed an overall homology of approximately 45%, with the majority of the homology located in the mature C terminal sequences (-70%) (8,18) . The individual precursor regions display several regions of homology with each other, particularly in the NH 2 -terminal half of the molecule. The /3 B precursor contains an unusually proline-rich sequence which is not present in the /3 A precursor. A similarly unusual sequence of lysine and glutamic acid repeats is contained near the COOH terminus of the /3 A precursor. Such unusual sequences have been seen in other proteins (19) (20) (21) (22) . The function of these repeat motifs is not known.
Transfection of a mammalian cell line with an expression vector containing the coding sequences for the postulated prepro form of the /3 B -subunit resulted in the secretion of an activin B homodimer. The subsequent purification of activin B from a stable cell line allowed for the first time a direct comparison of the biological activities of activin A and activin B. Analysis of these two compounds in the rat pituitary FSH release assay and the K562 differentiation assay reveals that they display virtually undistinguishable activities and biological potencies. We speculate that both activin A and activin B act through the same receptor in the pituitary and the erythropoietic assays. The 70% primary amino acid sequence identity must be sufficient to allow such interactions. The fact that both activin A and activin B are nearly 100% conserved in sequence among rodents, pigs, cows, and humans suggests that each of these molecules has as yet to be discovered individual functions (8, 18, 23, 24) . In situ hybridization experiments have revealed that the mRNA for j3 B , but not that for /3 A or a, is expressed in small antral follicles in the primate ovary (Schwall R. H., A. J. Mason, J. N. Wilcox, S. G. Bassett, A. J. Zelenick, unpublished observations). These data raise the possibility that activin B may be important in the early phases of follicular development. The availability of purified recombinant activin B and activin A should allow the testing of these compounds in a variety of assays, including effects on different primary and transformed ovarian and testicular cell lines. Once such an individual biological effect has been ascribed to one form of activin, hybrid molecules may be used to map functional domains in these two molecules. The apparent function of the precursor sequences of both of these molecules also remains to be elucidated. These sequences are cosecreted with activin from tissue culture cells and are probably noncovalently bound to the activin dimer.
In summary, recombinant activin B has been produced using recombinant DNA technology. The data presented here show that activin B, which has never been purified from natural sources, has the potential to modulate FSH secretion and act as an erythroid differentiation factor. The use of recombinant activin B to generate monoclonal antibodies specific for activin B should enable us to determine when and where it is produced in vivo. Such results may provide clues as to possible individual roles for activin A and activin B.
MATERIALS AND METHODS
Isolation of /3 B Genomic Clones
An end-labeled synthetic oligonucleotide of sequence 5'-GGATCCCCGGGTGGCTCGCAGGACACCTGTACGTCGTG-CGGCGGCTTCCGGCGGCCAGAGGAGCT-3' was used to sequence screen a total of 1 x 10 6 clones from a Charon 4A genomic library. Clones were screened, and positives were purified as described by Maniatis et al. (25) . A 12-kb EcoRI and a 4.2-kb SamHI fragment derived from the X clone A/3 B 5' were subcloned into the plasmid pBR322. Purified plasmid was used to perform multiple restriction digests. Digests were analyzed by agarose gel electrophoresis and Southern blotting (25) . A mixture of synthetic and cDNA-derived probes were used to map the exon-intron arrangement of the /3 B gene. Relevant fragments were subcloned into appropriate M13 vectors and sequences by the dideoxy method (26) . These included M13£ B -5', which contains the 5' coding sequence contained on a 575-b Pst\ fragment (Fig. 2) .
Assembly of 0 B Expression Vector and Transfections
The sequence AAGGCA, located 7 bp 3' of the /3 B stop codon, was changed by in vitro mutagenesis to an H/ndlll restriction site. This facilitated the removal of /3 B 3' untranslated region. Single stranded M13/3 B -3Hd DNA was made double stranded in a Klenow reaction using the universal 17-mer lac primer. The ds DNA was digested with HindWl and Pst\, and the 1099-bp fragment was purified by polyacrylamide gel electrophoresis (PAGE). This fragment was ligated to a similarly prepared 261-bp Nco\-Pst\ from M13/3 B 5' along with a 25-bp EcoRINco\ adaptor (sequence Fig. 2 ). The resultant 1385-bp EcoRI-H/ndlll fragment was cloned into the EcoRI and H/ndlll sites of the cytomegalovirus vector pRK5. Plasmid pRK/3 B was purified by CsCI gradients (Fig. 2) . The pRK5 expression vector contains the CMV enhancer, promoter, and splice donor sequence, and an immunoglobulin variable splice acceptor followed by the poly(A) addition site and transcription terminator of the early region of SV40 (15) .
Transient transfections were performed by the calcium phosphate precipitation method using 5 M9 CSCI gradientpurified plasmid per 60-mM dish (27) . Stable clones were selected from transfections which included 0.1 tig pRSV neo in 800 Mg/ml G418. Cells were cultured in either Dulbecco's Modified Eagle's Medium-Ham's F-12 (1:1) containing 10% fetal bovine serum or, for serum-free culture, Dulbecco's Modified Eagle's Medium-Ham's F-12 (1:1) plus 5 ng/m\ insulin.
Metabolic Labeling and Immune Precipitations
Transfected or stable clones were grown to confluency in a 60-mm dish and labeled for 1 h in 1 ml serum-free medium supplemented with 100-250 ftCi/ml [ . One hour later, cells were rinsed with PBS and chased for 5 h in 1 ml serum-free medium. Labeled supernatants were then either analyzed by sodium dodecyl sulfate-PAGE (SDS-PAGE) or immunoprecipitated before SDS-PAGE (28) . For the immunoprecipitations, a goat polyclonal antibody prepared against recombinant activin A was used. Fifty microliters of supernatant were incubated with 2 ng activin A-affinity-purified immunoglobulin G at room temperature for 1 h. Immune complexes were precipitated using protein A. Samples were boiled in SDS loading buffer for 3 min before analysis on 12% polyacrylamide SDS-gels. Polyacrylamide gels were fixed in acetic acid, treated with Enhance (New England Nuclear, Boston, MA), and dried before autoradiography.
Pituitary Cell Bioassay and K562 Bioassay
The ability of activin B to stimulate FSH secretion was assessed in cultured pituitary cells, as described previously (14) . Induction of hemoglobin was measured in the K562 human erythroleukemia cell line, as described previously (14) . Hemoglobin was measured by the method of Clarke et al. (29) . ED 50 values were derived using a four-parameter curve-fitting program based on the algorithm described by Marquardt (30) .
